These included a 58-year-old female with relapsed AITL (BCL2 positivity 30%) who received venetoclax for 4 months and experienced disease progression and a 77-year-old male with refractory PTCL-NOS (BCL2 positivity 40%) who is still receiving venetoclax 15 months since the beginning of treatment. This evidence concerns the gene BCL2 and angioimmunoblastic T-cell lymphoma.